These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 31326502)

  • 21. Identification, molecular characterization and segregation analysis of a variant
    Fontana L; Santoro M; D'Apice MR; Peluso F; Gori G; Morrone A; Novelli G; Dosa L; Botta A
    Acta Myol; 2020 Mar; 39(1):13-18. PubMed ID: 32607474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High Resolution Analysis of
    Rasmussen A; Hildonen M; Vissing J; Duno M; Tümer Z; Birkedal U
    Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA methylation at the
    Breton É; Légaré C; Overend G; Guay SP; Monckton D; Mathieu J; Gagnon C; Richer L; Gallais B; Bouchard L
    Epigenomics; 2020 Dec; 12(23):2051-2064. PubMed ID: 33301350
    [No Abstract]   [Full Text] [Related]  

  • 24. Reduced renal function in patients with Myotonic Dystrophy type 1 and the association to CTG expansion and other potential risk factors for chronic kidney disease.
    Aldenbratt A; Lindberg C; Svensson MK
    Neuromuscul Disord; 2017 Nov; 27(11):1038-1042. PubMed ID: 29029879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRISPR/Cas9-Induced (CTG⋅CAG)
    van Agtmaal EL; André LM; Willemse M; Cumming SA; van Kessel IDG; van den Broek WJAA; Gourdon G; Furling D; Mouly V; Monckton DG; Wansink DG; Wieringa B
    Mol Ther; 2017 Jan; 25(1):24-43. PubMed ID: 28129118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased expression of DMPK: correlation with CTG repeat expansion and fibre type composition in myotonic dystrophy type 1.
    Salvatori S; Fanin M; Trevisan CP; Furlan S; Reddy S; Nagy JI; Angelini C
    Neurol Sci; 2005 Oct; 26(4):235-42. PubMed ID: 16193250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myotonic dystrophy type 1 testing, 2024 revision: A technical standard of the American College of Medical Genetics and Genomics (ACMG).
    Seifert BA; Reddi HV; Kang BE; Bean LJH; Shealy A; Rose NC;
    Genet Med; 2024 Aug; 26(8):101145. PubMed ID: 38836869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in myotonic dystrophy protein kinase levels and muscle development in congenital myotonic dystrophy.
    Furling D; Lam le T; Agbulut O; Butler-Browne GS; Morris GE
    Am J Pathol; 2003 Mar; 162(3):1001-9. PubMed ID: 12598332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uncovering the Role of Hypermethylation by CTG Expansion in Myotonic Dystrophy Type 1 Using Mutant Human Embryonic Stem Cells.
    Yanovsky-Dagan S; Avitzour M; Altarescu G; Renbaum P; Eldar-Geva T; Schonberger O; Mitrani-Rosenbaum S; Levy-Lahad E; Birnbaum RY; Gepstein L; Epsztejn-Litman S; Eiges R
    Stem Cell Reports; 2015 Aug; 5(2):221-31. PubMed ID: 26190529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aberrant Myokine Signaling in Congenital Myotonic Dystrophy.
    Nakamori M; Hamanaka K; Thomas JD; Wang ET; Hayashi YK; Takahashi MP; Swanson MS; Nishino I; Mochizuki H
    Cell Rep; 2017 Oct; 21(5):1240-1252. PubMed ID: 29091763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diastolic heart dysfunction is correlated with CTG repeat length in myotonic dystrophy type 1.
    Park JS; Kim N; Park D
    Neurol Sci; 2018 Nov; 39(11):1935-1943. PubMed ID: 30094526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DM1 Phenotype Variability and Triplet Repeat Instability: Challenges in the Development of New Therapies.
    Tomé S; Gourdon G
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population-Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of Statewide Blood Screening Program.
    Johnson NE; Butterfield RJ; Mayne K; Newcomb T; Imburgia C; Dunn D; Duval B; Feldkamp ML; Weiss RB
    Neurology; 2021 Feb; 96(7):e1045-e1053. PubMed ID: 33472919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myotonic dystrophy: candidate small molecule therapeutics.
    Konieczny P; Selma-Soriano E; Rapisarda AS; Fernandez-Costa JM; Perez-Alonso M; Artero R
    Drug Discov Today; 2017 Nov; 22(11):1740-1748. PubMed ID: 28780071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antisense transcription of the myotonic dystrophy locus yields low-abundant RNAs with and without (CAG)n repeat.
    Gudde AEEG; van Heeringen SJ; de Oude AI; van Kessel IDG; Estabrook J; Wang ET; Wieringa B; Wansink DG
    RNA Biol; 2017 Oct; 14(10):1374-1388. PubMed ID: 28102759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Need for Establishing a Universal CTG Sizing Method in Myotonic Dystrophy Type 1.
    Ballester-Lopez A; Linares-Pardo I; Koehorst E; Núñez-Manchón J; Pintos-Morell G; Coll-Cantí J; Almendrote M; Lucente G; Arbex A; Magaña JJ; Murillo-Melo NM; Lucia A; Monckton DG; Cumming SA; Ramos-Fransi A; Martínez-Piñeiro A; Nogales-Gadea G
    Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32645888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2.
    Ranum LP; Day JW
    Curr Neurol Neurosci Rep; 2002 Sep; 2(5):465-70. PubMed ID: 12169228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A low absolute number of expanded transcripts is involved in myotonic dystrophy type 1 manifestation in muscle.
    Gudde AE; González-Barriga A; van den Broek WJ; Wieringa B; Wansink DG
    Hum Mol Genet; 2016 Apr; 25(8):1648-62. PubMed ID: 26908607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2.
    Kamsteeg EJ; Kress W; Catalli C; Hertz JM; Witsch-Baumgartner M; Buckley MF; van Engelen BG; Schwartz M; Scheffer H
    Eur J Hum Genet; 2012 Dec; 20(12):1203-8. PubMed ID: 22643181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Therapies for Myotonic Dystrophy Type 1: From Small Drugs to Gene Editing.
    Izzo M; Battistini J; Provenzano C; Martelli F; Cardinali B; Falcone G
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.